EUVIMEDEUVIMED entdecken
Crossref

Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications

Anjali D Deshmukh iD, Aaron S Kesselheim, Theodore Tsacogianis, Benjamin N Rome iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Anjali D Deshmukh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Omalizumab, Asthma, United States Food and Drug Administration, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Research and regulatory approval for pediatric uses of prescription drugs often lag years after adult approvals, during which time substantial off‐label use of medications in children can occur. We evaluated whether US Food and Drug Administration (FDA) regulatory actions affected the pediatric use of omalizumab, a biologic drug used to treat asthma.

Methods

In this serial cross‐sectional study, we identified quarterly cohorts of children (0–18 years) with moderate‐to‐severe asthma within two large national claims databases of those with commercial insurance and Medicaid from 2003 to 2019. Using an interrupted time‐series analysis, we fit segmented linear regression models to identify changes in the incidence of omalizumab use in 6–11‐year‐old children compared with 12–18‐year‐olds after two time points: (1) 2009Q3 when an FDA advisory committee voted against use for 6–11‐year‐old children and (2) 2016Q2 when FDA expanded omalizumab's labeling to include 6–11‐year‐old children.

Results

We identified 9298 new pediatric omalizumab users (84% Medicaid). Among 6–11‐year‐old children, the incidence of omalizumab use did not change following the FDA's initial review of evidence in 2009 and increased after 2016 Q2 FDA approval for this age group in both Medicaid (58 per 100 000 children with asthma, 95% confidence interval [CI] 27–89, p < 0.001) and commercial insurance (57 per 100 000, 95% CI 21–94, p = 0.003) compared with 12–18‐year‐old children.

Conclusions

The use of omalizumab among asthmatic children aged 6–11 years remained steady after FDA advisory committee concerns in 2009 and increased after FDA expanded the indication to include this population in 2016. Additional market incentives may help to ensure the timely generation of evidence and regulatory approval of medications for children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabAsthmaUnited States Food and Drug AdministrationAnti-Asthmatic AgentsOff-Label UseDrug ApprovalHumansChildUnited StatesAdolescentChild, PreschoolMaleCross-Sectional StudiesFemaleInfantDatabases, FactualMedicaidInfant, NewbornInterrupted Time Series Analysis

Stichwörter der Autor:innen

Food and Drug Administrationasthmabiologicoff‐label prescriptionsomalizumabpediatric

Substanzen

OmalizumabAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Georgia State University College of Law, Atlanta, Georgia, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Anjali D Deshmukh, Benjamin N Rome

Zitieren

APA

Deshmukh, A. D., Kesselheim, A. S., Tsacogianis, T., & Rome, B. N. (2024). Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70009

Vancouver

Deshmukh AD, Kesselheim AS, Tsacogianis T, Rome BN. Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70009

BibTeX
@article{Deshmukh2024,
  author = {Deshmukh, Anjali D and Kesselheim, Aaron S and Tsacogianis, Theodore and Rome, Benjamin N},
  title = {Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70009}
}
Kostenlos starten →